You are here

NKTR-214

Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial

Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial

Endpoints

Nektar Therapeutics

Bristol-Myers Squibb

Flag link:

Nektar shows durability of Opdivo combo in 18-month update

Nektar shows durability of Opdivo combo in 18-month update

Fierce Biotech

Nektar Therapeutics

Bristol-Myers Squibb

clinical trials

Flag link:

This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study

This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study

Investors Business Daily

Bristol-Myers Squibb

Nektar Therapeutics

clinical trials

Flag link:

A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo

A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo

BioCentury

Nektar Therapeutics

metastatic melanoma

Flag link:

Complete response rate in Nektar melanoma trial hits 34%

Complete response rate in Nektar melanoma trial hits 34%

Fierce Biotech

Flag link:

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

Bladder cancer readout sees Nektar shares hit

Bladder cancer readout sees Nektar shares hit

Fierce Biotech

Nektar Therapeutics

Bristol-Myers Squibb

Flag link:

Here's Why Nektar Therapeutics Surged Today

Here's Why Nektar Therapeutics Surged Today

Motley Fool

Nektar Therapeutics

Flag link:

The 20 Hottest Pipeline Drugs to Watch in 2019

The 20 Hottest Pipeline Drugs to Watch in 2019

BioSpace

VX-659 + tezacaftor + ivacaftor

valoctocogene roxaparvovec

Flag link:

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

BioCentury

Nektar Therapeutics

prostate cancer

Flag link:

Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst

Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst

Fierce Biotech

Nektar Therapeutics

Flag link:

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Forbes

Bristol-Myers Squibb

renal cell carcinoma

urothelial cancer

Flag link:

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

CP Wire

Nektar Therapeutics

Flag link:

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

Flag link:

How a Biotech Bummer Sent Nektar Therapeutics Stock South Today

How a Biotech Bummer Sent Nektar Therapeutics Stock South Today

Motley Fool

Nektar Therapeutics

Bristol-Myers Squibb

Flag link:

Why Alkermes Sunk Today

Why Alkermes Sunk Today

Motley Fool

Flag link:

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

Forbes

Bristol-Myers Squibb

Nektar Therapeutics

Flag link:

3 Promising Cancer Immunotherapies to Watch in 2018

3 Promising Cancer Immunotherapies to Watch in 2018

Yahoo/Motley Fool

immuno-oncology

Bristol-Myers Squibb

Flag link:

Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results

Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results

NASDAQ.com

Bristol-Myers Squibb

Flag link:

Pages